197 filings
Page 5 of 10
424B5
ppy8m 6v84rohocpf
12 Nov 19
Prospectus supplement for primary offering
4:13pm
6-K
pu3bvp m3
7 Nov 19
Affimed Announces Proposed Public Offering of Common Shares
5:11pm
424B5
0az3towmj3mhf49tjabq
7 Nov 19
Prospectus supplement for primary offering
5:01pm
6-K
3px8a9 i644
7 Aug 19
Condensed Consolidated Financial Statements
8:24am
6-K
en4mx5j lty3ha
27 Jun 19
Current report (foreign)
4:18pm
6-K
bsko2b frg8xsu
4 Jun 19
Affimed Announces Annual General Meeting of Shareholders
4:16pm
6-K
kq7i zyfkrjfvz
22 May 19
Current report (foreign)
7:37am
6-K
8ac ipcd2r8a175
17 Apr 19
Affimed Provides Regulatory Update on AFM11 Clinical Program
4:10pm
6-K
zb7iecq3
7 Jan 19
Actualizing the Untapped Potential of the Innate Immune System Affimed’s Approach to Advancing Immuno - oncology January 2019
7:01am
424B5
fi9kgpa
8 Nov 18
Prospectus supplement for primary offering
4:31pm
EFFECT
t5vuqd1r7cphz
8 Nov 18
Notice of effectiveness
12:15am
6-K
wapkfr8fltkj0
7 Nov 18
Condensed Consolidated Financial Statements
7:31am
UPLOAD
s4vm9213grzrwtf
6 Nov 18
Letter from SEC
12:00am
CORRESP
9npc8pcl rcl
5 Nov 18
Correspondence with SEC
12:00am
6-K
hv0o65
1 Nov 18
Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting
9:20am
F-3
09akjan8t0u
22 Oct 18
Shelf registration (foreign)
4:32pm
6-K/A
qohw h0as
16 Oct 18
Current report (foreign) (amended)
4:30pm
6-K
qjmfcy
9 Oct 18
Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
6:05am
CT ORDER
5p7az
17 Sep 18
Confidential treatment order
12:00am